Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
1.
Ren Fail ; 37(5): 772-6, 2015 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-25869054

RESUMEN

BACKGROUND: Acute heart failure (HF) syndromes are frequently complicated with cardiorenal syndromes. The aim of this study was to evaluate the performance of admission neutrophil gelatinase associated lipocalin (NGAL) levels to predict diuretic dose requirement and to predict the occurrence of acute kidney injury (AKI) in patients presenting with acute decompensated HF. METHODS: Patients admitted with HF symptoms between December 2010 and October 2011 were prospectively enrolled. Samples were obtained for NGAL and brain natriuretic peptide. Patients were followed up until discharge or for three days, whichever happened first. They were grouped either to have AKI according to "Acute Kidney Injury Network" criteria or not ("no-AKI"). RESULTS: One hundred patients were enrolled. Urine NGAL levels were higher in AKI group (median 31.3 vs. 16.2 ng/mL) (p < 0.001). Oral furosemide using rates on admission was 60.5% in AKI group, 31.6% in no-AKI group. More AKI developed in patients using less furosemide orally on admission (p = 0.023). Although the mean furosemide doses were similar on the first day (80 mg), diuretic dose increment was less on the following days in AKI group. Urine NGAL levels with 12 ng/mL cut-off value had sensitivity of 79% and specificity of 67% for predicting AKI. Multiple logistic regression analysis yielded an odds ratio of 10.9 for NGAL levels to predict AKI. CONCLUSION: Urine NGAL level in decompensated HF patients was not a significant predictor of diuretic dose requirement, but was a good marker for predicting AKI at 12 ng/mL cut-off value.


Asunto(s)
Lesión Renal Aguda/tratamiento farmacológico , Lesión Renal Aguda/etiología , Proteínas de Fase Aguda/orina , Furosemida/administración & dosificación , Insuficiencia Cardíaca/complicaciones , Lipocalinas/orina , Péptido Natriurético Encefálico/sangre , Proteínas Proto-Oncogénicas/orina , Anciano , Anciano de 80 o más Años , Biomarcadores/orina , Femenino , Humanos , Lipocalina 2 , Modelos Logísticos , Masculino , Persona de Mediana Edad , Oportunidad Relativa , Pronóstico , Estudios Prospectivos , Curva ROC , Sensibilidad y Especificidad
2.
Eur J Intern Med ; 25(6): 528-32, 2014 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-24814432

RESUMEN

BACKGROUND: Tetanus, diphtheria, pertussis and measles are vaccine preventable diseases that have been reported to cause morbidity and mortality in adult population in the recent years. We aimed to document the seropositivity rates and vaccination indication for these four vaccine preventable diseases among adult and elderly patients who were seen as outpatients in a university hospital. METHODS: Blood samples for tetanus, diphtheria, pertussis and measles antibodies were obtained. Results were evaluated with regards to protection levels and booster vaccine indications according to the cut-off values. RESULTS: A total of 1367 patients consented for the study and 1303 blood samples were available for analysis at the end of the study. The antibody levels against measles conferred protection in 98% of patients. However, 65% of the patients had no protection for diphtheria, 69% had no protection for tetanus and 90% of the patients had no protection for pertussis. Only 1.3% of the study population had seropositivity against three of the diseases-Tdap booster was indicated in 98.7%. Multivariable logistic regression showed that tetanus protection decreased with increasing age. Having a chronic disease was associated with a lower rate of protective antibodies for pertussis. CONCLUSIONS: We demonstrated very low rates of protection against three of the vaccine preventable diseases of childhood-diphtheria, pertussis and tetanus. Booster vaccinations are required in adult life in accordance with national and international adult vaccination guidelines. The concept of "lifelong vaccination" should be implemented and every encounter with the patient should be regarded as a chance for catch-up.


Asunto(s)
Anticuerpos/sangre , Bordetella pertussis/inmunología , Toxina Diftérica/inmunología , Vacunas contra Difteria, Tétanos y Tos Ferina Acelular/uso terapéutico , Virus del Sarampión/inmunología , Toxina Tetánica/inmunología , Adulto , Anciano , Difteria/epidemiología , Difteria/prevención & control , Femenino , Humanos , Inmunización Secundaria , Masculino , Persona de Mediana Edad , Evaluación de Necesidades , Estudios Seroepidemiológicos , Tétanos/epidemiología , Tétanos/prevención & control , Turquía/epidemiología , Tos Ferina/epidemiología , Tos Ferina/prevención & control
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA